GeneDx Holdings Corp.
$ 53.13
2.17%
02 Jun - close price
- Market Cap 1,543,777,000 USD
- Current Price $ 53.13
- High / Low $ 53.16 / 49.49
- Stock P/E N/A
- Book Value 10.54
- EPS -2.66
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.30 %
- 52 Week High 170.87
- 52 Week Low 32.21
About
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Analyst Target Price
$77.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-23 | 2025-10-28 | 2025-07-29 | 2025-04-30 | 2025-02-18 | 2024-10-29 | 2024-07-30 | 2024-04-29 | 2024-02-20 | 2023-10-30 | 2023-08-08 |
| Reported EPS | -0.28 | 0.14 | 0.49 | 0.5 | 0.2732 | 0.6353 | 0.04 | -0.1 | -0.33 | -0.69 | -0.82 | -1.64 |
| Estimated EPS | -0.0495 | 0.0886 | 0.41 | 0.118 | -0.67 | 0.1033 | -0.21 | -0.3 | -0.67 | -0.75 | -1.31 | -1.31 |
| Surprise | -0.2305 | 0.0514 | 0.08 | 0.382 | 0.9432 | 0.532 | 0.25 | 0.2 | 0.34 | 0.06 | 0.49 | -0.33 |
| Surprise Percentage | -465.6566% | 58.0135% | 19.5122% | 323.7288% | 140.7761% | 515.0048% | 119.0476% | 66.6667% | 50.7463% | 8% | 37.4046% | -25.1908% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WGS
2026-05-22 21:39:13
Eli Casdin and Keith Meister have disclosed updated significant ownership positions in GeneDx Holdings Corp. (WGS) through a Schedule 13D/A filing. Casdin reports beneficial ownership of 13.7% and Meister 17.9% of GeneDx's Class A common stock, including shares held through various investment entities, warrants, and restricted stock units. This filing highlights substantial institutional involvement and the specifics of their holdings, calculated based on 29,688,027 shares outstanding as of May 1, 2026.
2026-05-20 23:39:43
Investment entities associated with Casdin Capital, including Casdin Partners Master Fund, L.P., made open-market purchases of 500,000 shares of GeneDx Holdings Corp. (WGS) Class A Common Stock between May 18-20, 2026. These transactions, valued at over $21 million, increased the fund's indirect holdings to 3,507,164 shares, with Eli Casdin also holding direct and other indirect shares. The weighted average purchase prices were in the low-to-mid $40 range, indicating a positive sentiment from the insider buys.
2026-05-20 23:39:43
Casdin Partners Master Fund, L.P., an entity linked to GeneDx Holdings Corp. director Eli Casdin, recently acquired approximately 500,000 shares of GeneDx stock across three transactions for a total of $21.5 million. These purchases occurred between May 18 and May 20, 2026, amidst significant stock volatility and follows a 66% decline over the past six months. Despite recent earnings missing analyst expectations and revised guidance, the fund's continued investment highlights a notable insider transaction.
2026-05-18 06:10:31
GeneDx Holdings (NasdaqGS:WGS) is facing scrutiny after a significant Q1 2026 revenue miss and a sharp cut to its full-year guidance. Two law firms have launched investigations into potential securities fraud, focusing on whether previous optimistic statements were misleading. This situation highlights concerns about management credibility, disclosure quality, and potential financial and legal impacts for the genetic testing company.
2026-05-16 00:40:27
Corvex Management and director Keith Meister collectively purchased $13.7 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) Class A Common Stock between May 13 and May 15, 2026. These insider transactions occurred while the stock was trading near its 52-week low, following a significant 68% decline over the past six months. This comes after GeneDx reported lower-than-expected Q1 2026 earnings and revenue, leading to reduced price targets from analysts who nonetheless maintained Buy ratings.
2026-05-15 23:06:45
Investment funds advised by Corvex Management LP significantly increased their stake in GeneDx Holdings Corp. (WGS) by purchasing 351,273 Class A Common Stock shares through open-market transactions between May 13 and May 15, 2026. These purchases were made at weighted average prices ranging from $37.78 to $40.60 per share, bringing the total direct holdings of Corvex-advised funds to 4,784,570 shares. Keith A. Meister, a director and 10% owner, is associated with these holdings and also directly holds shares from vested restricted stock units.
